The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
Open accessAbstract
Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20,842 patients with coronary heart disease, 35,206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12,785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.Funding British Heart Foundation, UK Medical Research Council, Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the role of TG as a risk factor for CVD has been strongly debated, recent data strongly favour the role of TG-rich lipoproteins as a risk factor for CVD.121”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the CVD risk is increased if fasting TGs are . 1.7 mmol/ L (150 mg/dL), 87 the use of drugs to lower TGs may only be considered in high-risk subjects when TGs are . 2.3 mmol/L (200 mg/dL) and cannot be lowered by lifestyle measures.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of the current study extend those findings by suggesting that triglyceride-rich remnant particles have approximately the same effect on the risk of cardiovascular disease as LDL particles.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The association between triglycerides and cardiovascular (CV) risk is well established from epidemiological studies,1-5 genome-wide analyses,6-8 and Mendelian randomization studies.9,10”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization. 87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“Although the role of TGs as a risk factor for CVD has been strongly debated, recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.87”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Sattar, N. A., McConnachie, A., Shaper, A. G., Blauw, G. J., Buckley, B. M., de Craen, A. J. M., Ford, I., Forouhi, N. G., Freeman, D. J., Jukema, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60602-9 · Cited by 492
Keating, B. J., Tischfield, S. E., Murray, S. S., Bhangale, T., Price, T. S., Glessner, J., Galver, L., Barrett, J. C., Grant, S. F. A., Farlow, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003583 · Cited by 373
Cited by
Sorted by citations
Items 201–300 of 716
Niiranen, T., & Vasan, R. S. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1176528 · Cited by 49
Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology
Hubacek, J. A. (2016) · Gene · doi:10.1016/j.gene.2016.07.070 · Cited by 47
Karalis, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0462-y · Cited by 48
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
Triglyceride and cardiovascular risk: A critical appraisal
Singh, A. K., & Singh, R. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.183460 · Cited by 45
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
Current Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 44
Mendoza-Barberà, E., Julve, J., Nilsson, S. K., Lõokene, A., Martín-Campos, J. M., Roig, R., Lechuga-Sancho, A. M., Sloan, J. H., Fuentes‐Prior, P., & Blanco‐Vaca, F. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m031195 · Cited by 49
Kuba, M., Matsuzaka, T., Matsumori, R., Saito, R., Kaga, N., Taka, H., Ikehata, K., Okada, N., Kikuchi, T., Ohno, H., et al. (2015) · Scientific Reports · doi:10.1038/srep17604 · Cited by 46
Silbernagel, G., Scharnagl, H., Kleber, M. E., Delgado, G., Stojaković, T., Laaksonen, R., Erdmann, J., Rankinen, T., Bouchard, C., Landmesser, U., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.024 · Cited by 43
Johansen, M. Ø., Vedel‐Krogh, S., Nielsen, S. F., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315639 · Cited by 43
Tonkin, A. M., & Chen, L. (2010) · Circulation · doi:10.1161/circulationaha.110.960112 · Cited by 42
Ma, W., Ding, H., Gong, X., Liu, Z., Lin, Y., Zhang, Z., & Lin, G. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.034 · Cited by 43
Erbel, R. M., Lehmann, N., Churzidse, S., Möhlenkamp, S., Moebus, S., Mahabadi, A. A., Schmermund, A., Stang, A., Dragano, N., Grönemeyer, D. H. W., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.04.015 · Cited by 43
Schmedes, M. S., Brejnrod, A., Aadland, E. K., Kiilerich, P., Kristiansen, K., Jacques, H., Lavigne, C., Graff, I. E., Eng, Ø., Holthe, A., et al. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700976 · Cited by 43
Guallar‐Castillón, P., Oliveira, A., Lopes, C. M. M., López‐García, E., & Rodríguez‐Artalejo, F. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.11.035 · Cited by 45
PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia
IuA, K., & Владиславовна, Х. Ю. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0268-2 · Cited by 42
The Complex Genetic Basis of Plasma Triglycerides
Johansen, C. T., & Hegele, R. A. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0243-2 · Cited by 42
Rosenthal, E. A., Ranchalis, J., Crosslin, D. R., Burt, A., Brunzell, J. D., Motulsky, A. G., Nickerson, D. A., Wijsman, E. M., & Jarvik, G. P. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.10.019 · Cited by 42
Wang, Y., Shen, L., & Xu, D. (2018) · Clinical Cardiology · doi:10.1002/clc.23104 · Cited by 52
Dai, W., Zhang, Z., Yao, C., & Zhao, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1166-5 · Cited by 44
ApoB48 as an Efficient Regulator of Intestinal Lipid Transport
Lo, C. C., & Coschigano, K. T. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00796 · Cited by 42
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 43
Causal Relevance of Blood Lipid Fractions in the Development of Carotid Atherosclerosis
Shah, S. H., Casas, J. P., Drenos, F., Whittaker, J. C., Deanfield, J. E., Swerdlow, D. I., Holmes, M. V., Mika Kivimaki, B., Langenberg, C., Wareham, N. J., et al. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.112.963140 · Cited by 45
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 48
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Brautbar, A., Covarrubias, D., Belmont, J. W., Lara, F., Virani, S. S., Jones, P. H., Leal, S. M., & Ballantyne, C. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.08.015 · Cited by 40
Ewang-Emukowhate, M., & Wierzbicki, A. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413492906 · Cited by 39
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
MOGAT2: A New Therapeutic Target for Metabolic Syndrome
Yang, M., & Nickels, J. T. (2015) · Diseases · doi:10.3390/diseases3030176 · Cited by 38
ASSOCIATION OF INCREASED TRIGLYCERIDE LEVELS IN METABOLIC SYNDROME WITH CORONARY ARTERY DISEASE
Helvacı, M. R., Kaya, H., & Gündoğdu, M. A. (2010) · Pakistan Journal of Medical Sciences · Cited by 38
Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke
Williams, S. R., Hsu, F., Keene, K. L., Chen, W., Nelson, S. C., Southerland, A. M., Madden, E. B., Coull, B. M., Gogarten, S. M., Furie, K. L., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002319 · Cited by 39
Bittencourt, M. S., Santos, R. D., Staniak, H. L., Sharovsky, R., Kondapally, R., Vallejo‐Vaz, A. J., Ray, K. K., Benseñor, I. M., & Lotufo, P. A. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.01.033 · Cited by 38
You, Y., Wu, Y., Zhang, Y., Zhang, L., Song, Y., Bai, W., Li, Y., Yu, Y., & Kou, C. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020016 · Cited by 39
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 42
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 37
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 44
Wierzbicki, A. S., Clarke, R. E., Viljoen, A., & Mikhailidis, D. P. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328353adc1 · Cited by 39
Ong, K. L., Jiang, C. Q., Liu, B., Jin, Y. L., Tso, A. W. K., Tam, S., Wong, K. S., Tomlinson, B., Cheung, B. M. Y., Lin, J. M., et al. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03899.x · Cited by 39
Low High-Density Lipoprotein Cholesterol to Monitor Long-Term Average Increased Triglycerides
Langsted, A., Jensen, A. M. R., Varbo, A., & Nordestgaard, B. G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz265 · Cited by 39
The Hong Kong Diabetes Register TRS Study Group, Tam, C. H. T., The Hong Kong Diabetes Biobank Study Group, Lim, C. K. P., Luk, A. O. Y., Ng, A. C. W., Lee, H. M., Jiang, G., Lau, E. S. H., Fan, B., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00831-z · Cited by 37
Shirts, B. H., Hasstedt, S. J., Hopkins, P. N., & Hunt, S. C. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.03.008 · Cited by 37
Han, Y. Y., Dorajoo, R., Chang, X., Wang, L., Khor, C. C., Sim, X., Cheng, C., Shi, Y., Tham, Y. C., Zhao, W., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18214-z · Cited by 38
Kang, R., Kim, M., Chae, J. S., Lee, S.-H., & Lee, J. H. (2014) · Trials · doi:10.1186/1745-6215-15-100 · Cited by 36
2022 Taiwan lipid guidelines for primary prevention
Huang, P., Lu, Y., Tsai, Y., Wu, Y., Li, H., Chang, H.-Y., Wu, C., Yang, C., Tarng, D., Huang, C., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.05.010 · Cited by 37
Song, K. H., Yu, S.-G., Cha, S., & Kim, J. Y. (2011) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/598394 · Cited by 35
Non-HDL C equals apolipoprotein B: except when it does not!
Sniderman, A. D., Williams, K., & Graaf, J. D. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ee80c · Cited by 34
Peters, B. S., Wierzbicki, A. S., Moyle, G. J., Nair, D. R., & Brockmeyer, N. H. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.12.001 · Cited by 35
Orho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 39
Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason, R. P., Sherratt, S. C. R., & Eckel, R. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101681 · Cited by 39
Adipocyte Triglyceride Turnover Is Independently Associated With Atherogenic Dyslipidemia
Frayn, K. N., Bernard, S., Spalding, K. L., & Arner, P. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003467 · Cited by 35
Secondary hypertriglyceridemia in children and adolescents
Blackett, P. R., Wilson, D. P., & McNeal, C. J. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.006 · Cited by 35
Haas, B. E., Horvath, S., Pietiläinen, K. H., Cantor, R. M., Nikkola, E., Weissglas‐Volkov, D., Rissanen, A., Civelek, M., Cruz‐Bautista, I., Riba, L., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-61 · Cited by 35
Blom, W. A. M., Koppenol, W. P., Hiemstra, H., Stojaković, T., Scharnagl, H., & Trautwein, E. A. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1706-1 · Cited by 38
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 39
Mallat, Z. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304794 · Cited by 34
Residual risks and evolving atherosclerotic plaques
Noothi, S. K., Ahmed, M. R., & Agrawal, D. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04689-0 · Cited by 37
Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population
Ascaso, J. F., Millán, J., Mateo‐Gállego, R., Ruiz, A., Tembra, M. S., Borrallo, R. M., Zambón, D., González‐Santos, P., Peres-de-Juan, M., & Ros, E. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.12.011 · Cited by 34
Zhou, J., Xu, L., Huang, R. S., Huang, Y., Le, Y., Jiang, D., Yang, X., Xu, W., HUANG, X., Dong, C., et al. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1642 · Cited by 33
Dutta, D., Bhattacharya, S., Surana, V., Aggarwal, S., Singla, R., Khandelwal, D., & Sharma, M. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.08.039 · Cited by 33
Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)
Souto, S. B., Souto, E. B., Braga, D. C., & Medina, J. L. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1038-z · Cited by 36
Reimund, M., Kovrov, O., Olivecrona, G., & Lookene, A. (2017) · Journal of Lipid Research · doi:10.1194/jlr.d071787 · Cited by 32
Therapeutic targets of triglyceride metabolism as informed by human genetics
Bauer, R. C., Khetarpal, S. A., Hand, N. J., & Rader, D. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.005 · Cited by 32
Postprandial lipaemia and vascular disease
Kolovou, G., & Ooi, T. C. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283606971 · Cited by 32
Comparative Blood and Urine Metabolomics Analysis of Healthy Elderly and Young Male Singaporeans
Chen, L., Zhang, J., Teh, J. P. Y., Cheon, B. K., Yang, Y., Schlundt, J., Wang, Y., & Conway, P. L. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00215 · Cited by 32
Ghafouri, K. J., Cooney, J., Bedford, D. K., Wilson, J., CASLAKE, M. J., & Gill, J. M. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1196 · Cited by 34
Stauffer, M. E., Weisenfluh, L., & Morrison, A. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s52713 · Cited by 32
Beaney, K. E., Cooper, J. A., Shahid, S. U., Ahmed, W., Qamar, R., Drenos, F., Crockard, M. A., & Humphries, S. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130754 · Cited by 31
Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease
Lamprea-Montealegre, J. A., McClelland, R. L., Grams, M. E., Ouyang, P., Szklo, M., & de Boer, I. H. (2018) · Heart · doi:10.1136/heartjnl-2017-312794 · Cited by 33
Nelson, A. J., Návar, A. M., Mulder, H. S., WOJDYLA, D. M., Philip, S., Granowitz, C. B., Peterson, E. D., & Pagidipati, N. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.07.005 · Cited by 33
Nutrigenetic variants and cardio-metabolic risk in women with or without gestational diabetes
Franzago, M., Fraticelli, F., Marchetti, D., Celentano, C., Liberati, M., Stuppia, L., & Vitacolonna, E. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.001 · Cited by 32
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 31
Ali, Z., Ma, H., Wali, A., Ayim, I., & Sharif, M. N. (2019) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2019.100265 · Cited by 31
Gordillo‐Marañón, M., Zwierzyna, M., Charoen, P., Drenos, F., Chopade, S., Shah, T., Engmann, J., Casas, J. P., Chaturvedi, N., Papacosta, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25731-z · Cited by 32
Guardiola, M., Cofán, M., de Castro-Orós, I., Cenarro, A., Plana, N., Talmud, P. J., Masana, L., Ros, E., Civeira, F., & Ribalta, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.008 · Cited by 31
Skulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30
Ruiz‐García, A., Arranz-Martínez, E., López-Uriarte, B., Rivera-Teijido, M., Martinez, D., Dávila-Blázquez, G. M., Rosillo-González, A., Delgado, J. A. G.-P., Mariño-Suárez, J. E., Revilla-Pascual, E., et al. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.04.001 · Cited by 34
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 32
Mendelian randomisation, lipids, and cardiovascular disease
Harrison, S. C., Holmes, M. V., & Humphries, S. E. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60481-4 · Cited by 31
Understanding Hypertriglyceridemia: Integrating Genetic Insights
Alves, M., Laranjeira, F., & Correia‐da‐Silva, G. (2024) · Genes · doi:10.3390/genes15020190 · Cited by 35
Effect of energy expenditure on postprandial triacylglycerol in adolescent boys
Tolfrey, K., Bentley, C., Goad, M., Varley‐Campbell, J., Willis, S., & Barrett, L. A. (2011) · European Journal of Applied Physiology · doi:10.1007/s00421-011-1936-x · Cited by 29
Pharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 29
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 30
Goldberg, R. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.011 · Cited by 31
Aaseth, E., Halvorsen, S., Helseth, R., & Gravning, J. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf104 · Cited by 30
Mendelian randomization: Its impact on cardiovascular disease
Kawashiri, M., Tada, H., Nomura, A., & Yamagishi, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.04.007 · Cited by 28
Zanetti, D., Gustafsson, S., Assimes, T. L., & Ingelsson, E. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.002996 · Cited by 31
Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
Hermans, M. P., & Fruchart, J. (2010) · Clinical Lipidology · doi:10.2217/clp.10.65 · Cited by 28
Hu, S., Cui, G., Huang, J., Jiang, J.-G., & Wang, D. W. (2016) · Scientific Reports · doi:10.1038/srep32700 · Cited by 29
Psychophysiological Bases of Disease ☆
Steptoe, A., & Poole, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.05144-0 · Cited by 28
Postprandial VLDL-triacylglycerol secretion is not suppressed in obese type 2 diabetic men
Søndergaard, E., Sørensen, L. P., Rahbek, I., Gormsen, L. C., Christiansen, J. S., & Nielsen, S. (2012) · Diabetologia · doi:10.1007/s00125-012-2624-z · Cited by 27
Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care
Hartz, J. C., de Ferranti, S. D., & Gidding, S. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00079 · Cited by 29
Gao, R., Wu, Y., Huang, J., Song, L., Qian, H., Song, X., Cheng, L., Wang, R., Luo, L., Zhao, G., et al. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.01.065 · Cited by 27
Lambadiari, V., Korakas, E., & Tsimihodimos, V. (2020) · Nutrients · doi:10.3390/nu12082204 · Cited by 29
Zhao, T., & Zhao, J. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-120 · Cited by 27
Lipoprotein subclass profiles in young adults born preterm at very low birth weight
Hovi, P., Kajantie, E., Soininen, P., Kangas, A. J., Järvenpää, A., Andersson, S., Eriksson, J. G., Ala‐Korpela, M., & Wehkalampi, K. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-57 · Cited by 26
Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box
Chan, D. C., & Watts, G. F. (2011) · Metabolism · doi:10.1016/j.metabol.2011.07.014 · Cited by 26
Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study
Ruiz‐García, A., Arranz-Martínez, E., López-Uriarte, B., Rivera-Teijido, M., Martinez, D., Dávila-Blázquez, G. M., Rosillo-González, A., Delgado, J. A. G.-P., Mariño-Suárez, J. E., Revilla-Pascual, E., et al. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.11.002 · Cited by 26
Koohi, F., Khalili, D., Mansournia, M. A., Hadaegh, F., & Soori, H. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02966-4 · Cited by 26
Metadata
- Authors
- ‡
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- ‡
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9726
- Pages
- 1634-1639
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2867029
- OpenAlex
- W2144516660
- Cited by
- 716
- References
- 37
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 29 · 2023: 29 · 2022: 47 · 2021: 49 · 2020: 53 · 2019: 55 · 2018: 50 · 2017: 36 · 2016: 51 · 2015: 51 · 2014: 48 · 2013: 45 · 2012: 47
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-07-10)
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Explore Bristol Research (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Novartis
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- triglycerides, coronary artery disease, APOA5, APOA5 -1131T>C polymorphism, genetic association, triglyceride concentration, HDL cholesterol, apolipoprotein A-I, apolipoprotein B, lipoprotein concentration, lipoprotein particle size, causal inference, genetic risk factors
- MeSH terms
- Apolipoprotein A-V, Apolipoproteins, Apolipoproteins A, Coronary Disease, Gene Frequency, Genotype, Humans, Lipids, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Particle Size, Promoter Regions, Genetic, Risk Factors, Triglycerides, Polymorphism, Single Nucleotide, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
